Naftazone is a naphtoquinone derivative which was originally registered in several European countries for treating symptoms of varicose veins and venous insufficiency, based on its venoconstrictive properties. ts venotonic mechanism of action remains unknown, but the drug has anti‐inflammatory effects and inhibits platelet aggregation. Naftazone is shown to accelerate human saphenous vein endothelial cell proliferation in vitro at concentrations which did not alter the hemostatic balance. Naftazone, which exhibits glutamate release inhibition properties, has shown antiparkinsonian and antidyskinetic activity in preclinical models of Parkinson's disease and in a clinical proof of concept study. Naftazone is currently marketed in several countries.